Relay Therapeutics

$37.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.60 (-6.50%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RLAY and other stocks, options, and ETFs commission-free!

About RLAY

Relay Therapeutics, Inc. Common Stock, also called Relay Therapeutics, is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA. The listed name for RLAY is Relay Therapeutics, Inc. Common Stock.

CEO
Sanjiv K. Patel
Employees
122
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
3.25B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
758.63K
High Today
$39.08
Low Today
$33.56
Open Price
$38.98
Volume
1.20M
52 Week High
$64.37
52 Week Low
$32.56

RLAY Earnings

-$3.00
-$2.00
-$1.00
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, After Hours

You May Also Like

EPAC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure